The Director of Delhi AIIMS, Dr. Randeep Guleria, told India Today TV that the country can expect a vaccine for children by September.
AIIMS Chief said that Covaxin’s data for children after completion of the Phase 2/3 trials will be available by September and the approval is expected same month.
He also said that If Pfizer-BioNTech’s vaccine gets a green signal in India then that could also be an option for children.
Guleria also said that Delhi AIIMS has already started screening children for these trials. This started on June 7 and involves children between the age of 2 to 17.
On May 12, the DCGI had granted permission to Bharat Biotech to carry out phase 2, phase 3 trials of Covaxin on children as young as two.
Dr. Randeep Guleria also said that policymakers must now look at opening up schools in a way that would prevent institutes from becoming super-spreader events. When asked about opening up schools, he said, “a holistic approach has to be taken.”